IRIS
TROIANO, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.147
AS - Asia 10.264
EU - Europa 8.045
SA - Sud America 2.928
AF - Africa 554
Continente sconosciuto - Info sul continente non disponibili 32
OC - Oceania 27
Totale 50.997
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.779
SG - Singapore 4.183
CN - Cina 2.385
RU - Federazione Russa 2.313
BR - Brasile 2.283
HK - Hong Kong 1.291
SE - Svezia 1.200
IT - Italia 931
DE - Germania 707
VN - Vietnam 697
FR - Francia 624
FI - Finlandia 613
GB - Regno Unito 555
UA - Ucraina 496
IN - India 336
AR - Argentina 244
BD - Bangladesh 226
CI - Costa d'Avorio 203
CA - Canada 167
IQ - Iraq 150
ID - Indonesia 139
JP - Giappone 123
TR - Turchia 118
EC - Ecuador 109
MX - Messico 108
ZA - Sudafrica 108
NL - Olanda 103
PK - Pakistan 98
CO - Colombia 92
BE - Belgio 83
SA - Arabia Saudita 81
ES - Italia 76
VE - Venezuela 69
PL - Polonia 61
AT - Austria 58
PH - Filippine 56
IR - Iran 52
UZ - Uzbekistan 51
IE - Irlanda 50
TN - Tunisia 46
MA - Marocco 44
CL - Cile 38
JO - Giordania 38
MY - Malesia 38
EG - Egitto 36
LT - Lituania 34
PY - Paraguay 32
KE - Kenya 28
EU - Europa 24
PE - Perù 24
AU - Australia 21
AE - Emirati Arabi Uniti 20
IL - Israele 20
OM - Oman 20
CZ - Repubblica Ceca 19
ET - Etiopia 18
JM - Giamaica 18
UY - Uruguay 17
BO - Bolivia 16
KZ - Kazakistan 16
CR - Costa Rica 14
DO - Repubblica Dominicana 14
NP - Nepal 14
BG - Bulgaria 13
LB - Libano 13
PT - Portogallo 13
AL - Albania 12
AZ - Azerbaigian 12
DZ - Algeria 12
GR - Grecia 12
PA - Panama 12
PS - Palestinian Territory 12
RO - Romania 12
SN - Senegal 12
KR - Corea 10
TT - Trinidad e Tobago 10
AO - Angola 9
CH - Svizzera 9
KG - Kirghizistan 8
TH - Thailandia 8
BH - Bahrain 7
HU - Ungheria 7
BB - Barbados 6
EE - Estonia 6
GE - Georgia 6
NG - Nigeria 6
NZ - Nuova Zelanda 6
SY - Repubblica araba siriana 6
MD - Moldavia 5
QA - Qatar 5
XK - ???statistics.table.value.countryCode.XK??? 5
BY - Bielorussia 4
DK - Danimarca 4
HN - Honduras 4
HR - Croazia 4
KW - Kuwait 4
LK - Sri Lanka 4
MK - Macedonia 4
RS - Serbia 4
SR - Suriname 4
Totale 50.917
Salva come PNG Salva come JPEG
Città #
Fairfield 3.851
Ashburn 2.761
Woodbridge 2.754
Singapore 2.154
Houston 1.837
Chandler 1.816
Seattle 1.530
Cambridge 1.299
Hong Kong 1.291
Wilmington 1.198
Jacksonville 1.163
Ann Arbor 1.141
San Jose 1.066
Nyköping 895
Dallas 845
Beijing 627
Lawrence 448
Roxbury 432
Lauterbourg 411
Nanjing 381
New York 316
Los Angeles 314
Des Moines 301
Boardman 269
Helsinki 243
Princeton 238
Bari 231
Abidjan 203
São Paulo 199
Ho Chi Minh City 195
San Diego 172
Council Bluffs 158
Brooklyn 155
Santa Clara 152
Inglewood 148
Buffalo 134
Hanoi 129
London 125
Munich 124
Tokyo 113
Chicago 93
Shenyang 93
Hebei 91
Nuremberg 88
Rio de Janeiro 88
Norwalk 86
Dong Ket 85
Nanchang 85
Frankfurt am Main 83
Moscow 81
Jakarta 80
Brussels 76
Dearborn 75
Jiaxing 72
Paris 69
Guangzhou 67
Tianjin 67
Baghdad 61
Orem 61
Falkenstein 58
North Bergen 56
Toronto 56
Dhaka 54
Johannesburg 50
Changsha 49
Montreal 49
Amsterdam 48
Atlanta 46
Belo Horizonte 46
Columbus 46
Dublin 46
Warsaw 46
Quito 44
San Francisco 44
Shanghai 40
The Dalles 40
Pune 37
Tashkent 37
Jeddah 36
Stockholm 36
Rome 35
Washington 35
Denver 34
Salt Lake City 34
Chennai 33
Milan 33
Brasília 32
Marseille 32
Medellín 32
Amman 31
Curitiba 31
Da Nang 31
Lahore 30
Phoenix 30
Wuhan 30
Caracas 28
Mexico City 28
Poplar 28
New Delhi 27
Buenos Aires 26
Totale 34.904
Salva come PNG Salva come JPEG
Nome #
A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis 814
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study 755
Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study 321
The role of sexual dysfunction and attachment style in migraine related quality of life 247
Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study 239
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport 229
Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. 229
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis 226
A pattern of cognitive deficits stratified for genetic and environmental risk reliably classifies patients with schizophrenia from healthy control subjects 216
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice 215
Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis 211
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 210
Signs and symptoms of COVID-19 in patients with multiple sclerosis 210
AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding 206
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 206
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 191
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 189
DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient 189
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 189
Autophagy markers LC3 and p62 accumulate in immune‐mediated necrotizing myopathy 189
Assessing response to interferon-β in a multicenter dataset of patients with MS 188
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? 185
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 182
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 180
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 179
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 179
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 179
Prognostic indicators in pediatric clinically isolated syndrome 179
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 178
A rare case of multiple sclerosis and McArdle disease 178
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 177
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes 177
Age-related changes of serum N-acetyl-aspartate in healthy controls. 175
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 167
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis 166
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 166
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview 165
Age-related disability in multiple sclerosis 165
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis 163
Investigating the role of microRNA and transcription factor co-regulatory networks in multiple sclerosis pathogenesis 163
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 160
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 160
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 159
A systematic review of the incidence and prevalence of cancer in multiple sclerosis 158
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 157
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 155
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 155
A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis 155
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 155
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 155
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis 154
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 152
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 149
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 148
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 148
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 147
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients 145
A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy 145
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS 145
Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers 145
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 145
Comparative efficacy of switching to natalizumab in active multiple sclerosis 143
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 143
Tissue distribution of the readthrough isoform of AQP4 reveals a dual role of AQP4ex limited to CNS 143
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 142
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 142
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 142
Caregiver quality of life in multiple sclerosis: a multicentre Italian study 141
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis 141
Multiple sclerosis registries in Europe – An updated mapping survey 141
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review 140
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 140
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 139
Risk knowledge in relapsing multiple sclerosis (RIKNO 1.0) - Development of an outcome instrument for educational interventions 138
Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. 137
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 136
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 136
Natalizumab discontinuation and disease restart in pregnancy: A case series 136
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 135
Treatment decisions in multiple sclerosis-insights from real-world observational studies 135
The brief international cognitive assessment for multiple sclerosis (BICAMS): Normative values with gender, age and education corrections in the Italian population 134
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 134
A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis 134
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 133
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study 132
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 132
Apolipoprotein E genotype does not influence the progression of multiple sclerosis 131
Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis 130
Sclerosi Multipla e Lavoro: dati preliminari 130
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 130
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care 129
Defining reliable disability outcomes in multiple sclerosis 129
Epstein-Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role? 128
Psychosocial issue in children and adolescents with multiple sclerosis 128
Treating multiple sclerosis with natalizumab. 128
Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP) 128
A genome screen for multiple sclerosis in Italian families. 128
Development and validation of the ID-EC - The ITALIAN version of the identify chronic migraine 128
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis 127
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 127
Totale 17.414
Salva come PNG Salva come JPEG
Categoria #
all - tutte 210.944
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 210.944
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.395 0 0 0 0 0 0 0 0 0 655 418 322
2021/20223.282 235 422 48 80 144 289 174 172 237 210 532 739
2022/20234.809 779 506 297 427 616 590 66 558 714 30 126 100
2023/20241.647 153 312 108 110 144 354 60 59 30 63 29 225
2024/20257.632 321 145 641 302 238 631 586 638 373 423 1.102 2.232
2025/202615.587 2.257 776 1.514 1.799 1.654 954 1.780 541 2.886 1.426 0 0
Totale 52.546